TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01491113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 250 mg
Description: Tablet containing Levetiracetam 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 250 mg
Description: Tablet containing Levetiracetam 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 250 mg
Description: Tablet containing Levetiracetam 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 500 mg
Description: Tablet containing Levetiracetam 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 500 mg
Description: Tablet containing Levetiracetam 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 500 mg
Description: Tablet containing Levetiracetam 500 mg
Study: NCT02980809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topotecan
Study: NCT01810614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADPKD Diet
Description: Diet specifically designed for people with ADPKD
Study: NCT04620213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Ophthalmic Solution 0.75%
Description: 0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
Study: NCT01209026

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin placebo
Description: Film coated oral tablet
Study: NCT04620213

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phentolamine Ophthalmic Solution Vehicle (Placebo)
Description: Topical sterile ophthalmic solution
Study: NCT00712400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005%, Xalatan®
Description: Substance: Latanoprost 0.005%, Xalatan® (Pharmacia Austria Ges.m.b.H. Oberlaaer Straße 251, 1101 Vienna) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Substance: Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
Study: NCT01473680

Intervention type: OTHER
Intervention: EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire
Description: Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.

Intervention type: OTHER
Intervention: EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire
Description: Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.

Intervention type: OTHER
Intervention: EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire
Description: Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
Study: NCT00564057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan
Description: tablet 8-16 mg once daily, one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lercanidipine
Description: tablets 10-20 mg once daily, one year
Study: NCT04347668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: VR requires the user to use a multi-projected in their own room using BroomX to generate realistic images, sounds and other sensations that simulate a user's physical presence in a virtual or imaginary environment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: meals, engagement in scheduled and non-scheduled programs such as exercise, and activities, groups. Residents are supported in their activities of daily living, and social engagement. Specific interventions based on resident needs are supported in a Dementia capable environment.
Study: NCT01317550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 150 mg by mouth once a day for a 10 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 150 mg by mouth once a day for a 10 week cycle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules taken by mouth once a day for a 10 week cycle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules taken by mouth once a day for a 10 week cycle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules taken by mouth once a day for a 10 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg by mouth twice a day for a 10 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg by mouth twice a day for a 10 week cycle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of symptom questionnaire before chemoradiation, then once a week during Weeks 1-16, takes up to 5 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of symptom questionnaire before chemoradiation, then once a week during Weeks 1-16, takes up to 5 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of symptom questionnaire before chemoradiation, then once a week during Weeks 1-16, takes up to 5 minutes to complete.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Completion of symptom questionnaire before chemoradiation, then once a week during Weeks 1-16, takes up to 5 minutes to complete.
Study: NCT03963167

Intervention type: DRUG
Intervention: BDP/FF/G fixed combination
Description: Fixed combination of Inhaled Corticosteroid (ICS) / Long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) that contains Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (G).
Study: NCT02551510

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: Skin incision closure with standard subcuticular technique

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Histoacryl®
Description: Skin incision closure with topic skin adhesive Histoacryl® Flexible (n-Butyl-2-Cyanoacrylate Monomer)
Study: NCT03741166

Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Subjects participating in the study will have blood drawn at enrollment.
Study: NCT00488787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketamine
Description: low dose
Study: NCT03071757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-368
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-368
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-368
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-368
Description: Intravenous infusion
Study: NCT00488787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketamine
Description: medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketamine
Description: high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01505998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine Besylate/Benazepril HCl
Description: Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine Besylate/Benazepril HCl
Description: Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
Study: NCT03219866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nebulizers
Description: Patients treated and discharged on nebulized bronchodilators

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Powder Inhaler
Description: Patients treated and discharged on Dry Powder Inhalers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brovana
Description: Subjects will receive a long-acting B2-agonist(LABA; Brovana, twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmicort
Description: Subjects will receive a corticosteroid (ICS; Pulmicort, twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrovent
Description: Subjects will receive a short-acting anti-cholinergic (SAMA; Atrovent, three times a day)
Study: NCT03071757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-368
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous infusion
Study: NCT02908490

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil 50 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil 50 mg once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill
Study: NCT00756912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5564
Description: Three dose levels of Eritoran IV over 14 days for a total of 32, 96, and 224 mg over 14 days.
Study: NCT04664764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degludec
Description: Basal insulin comparison

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Basal insulin comparison

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: Basal insulin comparison
Study: NCT05729867

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscpic biliary drainage using fully covered metal stent
Description: After selective cannulation of the bile duct, cholangiography is obtained using contrast agent.~A guide wire is passed through the stricture, and then fully-covered metal stent is inserted under fluoroscopy guidance during ERCP.
Study: NCT01056302

Intervention type: PROCEDURE
Intervention: Surgical repair of mandibular fractures
Description: Patients will undergo whatever needed surgical repair of maxillofacial trauma that is necessary. Records such as CT imaging and plaster models of the jaws will be utilized in the standard way to plan and carry out the surgery. The CT scan will also be used within the visuohaptic computational environment to develop and evaluate the user interface. The amount of time taken to work up and plan surgery using standard surgical practice and using the computational platform will be compared. Real surgical outcome will be compared to the simulated surgical outcome using the proposed software tool.
Study: NCT02651909

Intervention type: OTHER
Intervention: blood sampling
Description: blood sampling for TEG analysis, Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay

Intervention type: OTHER
Intervention: blood sampling
Description: blood sampling for TEG analysis, Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
Study: NCT01057875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caffeine
Description: Starbuck's Grande Pike Roast coffee

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No caffeine
Description: Starbuck's Grande Pike Roast Decaffeinated Coffee
Study: NCT05704569

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of multiple biomarkers
Description: All patients were tested for glucose and cholesterol levels. The capillary blood glucose level was measured by an electrochemical method using an Accu-Chek Active by AkkuChek blood glucose meter. The DM was considered to be verified when there were criteria which the World Health Organization (WHO) set in 2001: glucose concentration in whole blood is \>6.1 mmol/l, and glucose concentration is \>11.1 mmol/l in random measurement. Plasma for the study was obtained via the standard phlebotomy technique from ethylenediaminetetraacetic acid (EDTA) anticoagulants. Plasma was aliquoted into cryovials and got frozen quickly. The samples were stored in a low-temperature refrigerator (-70°C) until the study commencement (up to 3 months). All biomarkers were measured by magnetic bead-based multiplex immunofluorescence assay through the Xmap technology using the Milliplex map Human CVD Magnetic Bead Panel 1 (Millipore)

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of multiple biomarkers
Description: All patients were tested for glucose and cholesterol levels. The capillary blood glucose level was measured by an electrochemical method using an Accu-Chek Active by AkkuChek blood glucose meter. The DM was considered to be verified when there were criteria which the World Health Organization (WHO) set in 2001: glucose concentration in whole blood is \>6.1 mmol/l, and glucose concentration is \>11.1 mmol/l in random measurement. Plasma for the study was obtained via the standard phlebotomy technique from ethylenediaminetetraacetic acid (EDTA) anticoagulants. Plasma was aliquoted into cryovials and got frozen quickly. The samples were stored in a low-temperature refrigerator (-70°C) until the study commencement (up to 3 months). All biomarkers were measured by magnetic bead-based multiplex immunofluorescence assay through the Xmap technology using the Milliplex map Human CVD Magnetic Bead Panel 1 (Millipore)
Study: NCT04442035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-element music therapy
Description: participants were treated by TCM five-phase music therapy for not less than 30 minutes per day, and group music therapy was performed every three weeks. In addition, the therapeutic schedule is composed of treatment time (1pm-2pm, 9pm-11pm), frequency treatment (two times a day), intervention (10-15 minutes in the afternoon, 30 minutes in the evening) and content (individuals: dialectical selection of music; groups: community singing, every three weeks).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-element music therapy
Description: participants were treated by TCM five-phase music therapy for not less than 30 minutes per day, and group music therapy was performed every three weeks. In addition, the therapeutic schedule is composed of treatment time (1pm-2pm, 9pm-11pm), frequency treatment (two times a day), intervention (10-15 minutes in the afternoon, 30 minutes in the evening) and content (individuals: dialectical selection of music; groups: community singing, every three weeks).
Study: NCT03135119

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TF-CBT
Description: TF-CBT is typically described as including 3 phases, each focusing on a common goal and encompassing a third of treatment (4 sessions). The first phase focuses on skills-building and includes psychoeducation, parenting skills training, relaxation skills training, affect modulation skills training, and cognitive coping skills training. The second phase involves focused gradual exposure activities, including construction of a narrative account of the child's maltreatment experiences and cognitive processing of maladaptive thoughts. The third phase emphasizes the child's mastery over environmental reminders of the maltreatment and includes sharing the trauma narrative with the caregiver, in vivo exposure to physical stimuli, and enhancing future development.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TF-CBT+AAT
Description: TF-CBT, as described in the other arm, with animal-assisted therapy as an adjunct intervention. During the administration of TF-CBT, a certified service dog will be in the room and the participant may elect to interact with the dog as various points throughout the sessions.
Study: NCT01478048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Solution; Intravenous (IV); 10 mg/kg; (Cycles 1 \& 2: Days 1, 8 \& 15; Cycles 3-8: Days 1 \& 11; Cycle 9+: Days 1 \& 15); Until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Solution; IV; 1.3 mg/m2; (Cycles 1 - 8: Days 1, 4, 8, 11; Cycles 9+: Days 1, 8, 15); Until subject meets criteria for discontinuation of study drug
Study: NCT04221477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered by IV infusion at a dose of 1000 mg at Baseline and Weeks 2, 24, 26, 50 (group 2: placebo), and 52 and subsequently from Week 80 and every 6 months thereafter, based on response.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered by IV infusion at a dose of 1000 mg at Baseline and Weeks 2, 24, 26, 50 (group 2: placebo), and 52 and subsequently from Week 80 and every 6 months thereafter, based on response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: MMF willl be administered at a target dose of 2.0 - 2.5 g/day in divided doses through Week 80.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MMF
Description: MMF willl be administered at a target dose of 2.0 - 2.5 g/day in divided doses through Week 80.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 0.5 mg/kg/day (maximum 60 mg/day) will be started on Day 2. Beginning on Day 15, prednisone will be tapered to 5 mg/day and continued until Week 80.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone 0.5 mg/kg/day (maximum 60 mg/day) will be started on Day 2. Beginning on Day 15, prednisone will be tapered to 5 mg/day and continued until Week 80.
Study: NCT01478048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Solution; IV; 1.3 mg/m2; (Cycles 1 - 8: Days 1, 4, 8, 11; Cycles 9+: Days 1, 8, 15); Until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets; Oral; 20 mg; (Cycles 1\& 2: once daily on Days 2, 4, 5, 8, 9, 11; Cycles 3-8: once daily on Days 2, 4, 5, 9, 12; Cycles 9+: once daily on Days 2, 8, 9, 16); Until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets; Oral; 8 mg; (Cycles 1\& 2: Days 1, 8, 15; Cycles 3-8: Days 1 \&11; Cycles 9+; Days 1 \& 15); Until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Solution; IV; 8 mg; (Cycles 1\& 2: Days 1, 8, 15; Cycles 3-8: Days 1 \&11; Cycles 9+; Days 1 \& 15); Until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Tablets; Oral; 20 mg; (Cycles 1-8 once daily on Days 1, 2, 4, 5, 8, 9, 11, 12; Cycles 9+ once daily on Days 1, 2, 8, 9, 15, 16); Until subject meets criteria for discontinuation of study drug
Study: NCT03219866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advair Diskus
Description: Subjects will receive a LABA/ICS (Advair Diskus, twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiriva HandiHaler
Description: Subjects will receive a long-acting anticholinergic (LAMA-Spiriva Handihaler, once daily)
Study: NCT03170752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular Assessment Screening Program (CASP)
Description: Step 1. Identification of patients; Step 2. Screening utilizing appropriate tools; and Step 3. Actions to follow up on the screening results.
Study: NCT01762566

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: wheat
Description: wheat is administered blindly versus placebo in capsules once

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: wheat
Description: wheat is administered blindly versus placebo in capsules once

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: xylose
Description: placebo (xylose) will be administered blindly versus wheat in a capsule once
Study: NCT03873740

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 inactived vaccine（Vero cells）
Description: The EV71 inactived vaccine（Vero cells） was manufactured by Sinovac Biotech Co., Ltd.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 inactived vaccine（Vero cells）
Description: The EV71 inactived vaccine（Vero cells） was manufactured by Sinovac Biotech Co., Ltd.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 inactived vaccine（Vero cells）
Description: The EV71 inactived vaccine（Vero cells） was manufactured by Sinovac Biotech Co., Ltd.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 inactived vaccine（Human diploid cells）
Description: The EV71 inactived vaccine（Human diploid cells） was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 inactived vaccine（Human diploid cells）
Description: The EV71 inactived vaccine（Human diploid cells） was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 inactived vaccine（Human diploid cells）
Description: The EV71 inactived vaccine（Human diploid cells） was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.